World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
26560
World Ranking
13696
National Ranking
6956

Luis Fayad publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Luis Fayad sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 592 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Luis Fayad D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Luis Fayad sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Luis Fayad is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a significant emphasis on Oncology, Pathology and Forensic Medicine, Genetics, Immunology, and Molecular Biology.

The scientist's main areas of work include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Immune Cell Function and Interaction

Fayad has contributed extensively to academic publications, appearing frequently in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Leukemia & Lymphoma, and International Journal of Radiation Oncology*Biology*Physics.

Their recent notable papers include:

  • "Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas," 2020, Nature Medicine
  • "Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma," 2020, Blood Advances
  • "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma," 2021, Blood
  • "A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy," 2023, Nature Medicine
  • "NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021," 2021, Journal of the National Comprehensive Cancer Network

The scientist frequently collaborates with a group of co-authors, including:

  • Sattva S. Neelapu
  • Jason R. Westin
  • Loretta J. Nastoupil
  • Christopher R. Flowers
  • Sairah Ahmed

Best Publications

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

    Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad

  • Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

    Catherine M. Bollard;Catherine M. Bollard;Stephen Gottschalk;Stephen Gottschalk;Vicky Torrano;Vicky Torrano;Oumar Diouf;Oumar Diouf

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

    Yasuhiro Oki;Mansoor Noorani;Pei Lin;Richard E. Davis

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

    Roberto N. Miranda;Tariq N. Aladily;H. Miles Prince;Rashmi Kanagal-Shamanna

  • Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.

    Qing Deng;Guangchun Han;Nahum Puebla-Osorio;Man Chun John Ma

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

    Jonathan W. Friedberg;Philip Cohen;Ling Chen;K. Sue Robinson

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

    Issa F Khouri;Peter McLaughlin;Rima M Saliba;Chitra Hosing

  • Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis

    Eleni Diamandidou;Maria Colome-Grimmer;Luis Fayad;Madeleine Duvic

  • Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

    Luis E Fayad;Michael J. Keating;James M. Reuben;Susan O'Brien

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

    Jorge E. Romaguera;Luis E. Fayad;Lei Feng;Kimberly Hartig

  • Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

    Jorge E. Romaguera;L. Jeffrey Medeiros;Frederick B. Hagemeister;Luis E. Fayad

  • Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy

    Jack Phan;Ali Mazloom;L Jeffrey Medeiros;Tony G. Zreik

Frequent Co-Authors

Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Larry W. Kwak
Larry W. Kwak City Of Hope National Medical Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Andre Goy
Andre Goy Hackensack University Medical Center
Fernando Cabanillas
Fernando Cabanillas The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a traditional medical degree is a popular path, there are several related online degrees that can lead to promising healthcare careers in the USA. For those interested in health leadership, exploring the cheapest online healthcare administration degree programs can open doors to administrative and management roles in hospitals and clinics.

Advancing further, earning an MHA is a smart move for career growth. Be sure to consider the mha degree cost to find affordable, accredited programs that fit your budget.

For registered nurses aiming for a higher degree, the best online bsn to dnp programs offer a flexible path to advanced practice and leadership roles.

If pharmacy interests you, consider researching accredited online pharmacist programs that combine affordability with quality education, allowing you to study at your own pace.

With a range of cost-effective online health programs available, finding the right path for your career goals in medicine and healthcare is easier than ever.

Best Scientists Citing Luis Fayad

Trending Scientists

Recently Published Articles